DIAS PUTRI WARDANASARI, 051511133114 (2019) COST OF ILLNESS PADA PASIEN DIABETES MELITUS TIPE 2 DENGAN TERAPI TUNGGAL GOLONGAN SULFONILUREA DI BEBERAPA PUSKESMAS WILAYAH SURABAYA. Skripsi thesis, Universitas Airlangga.

	Text (ABSTRACT) KKB KK-2 FF.Kom.14-19 War c ABSTRAK.pdf Download (16kB)
	Text (DAFTAR ISI) KKB KK-2 FF.Kom.14-19 War c DAFTAR ISI.pdf Download (58kB)
	Text (DAFTAR PUSTAKA) KKB KK-2 FF.Kom.14-19 War c DAFTAR PUSTAKA.pdf Download (110kB)
	Text (FULLTEXT) KKB KK-2 FF.Kom.14-19 War c SKRIPSI.pdf Restricted to Registered users only until 27 September 2022. Download (1MB) | Request a copy

Abstract

This study aimed to determine the cost of illness in patients Diabetes Mellitus Type 2 with monotherapy of sulphonylurea at 10 primary health care centre that have the highest number of DM patients in the Surabaya. This study was a cross sectional study using total sampling. Calculation cost of illness uses a list of questions. This study was conducted on 30 patients with Diabetes Mellitus Type 2 at 10 primary health care centre in the Surabaya. Sulphonylureas prescribed at several primary health care centre were Glibenklamid and Glimepirid. Total cost in type 2 Diabetes Mellitus patients with sulphonylurea monotherapy at several primary health care centre in Surabaya was Rp25.684.718,-/year. The biggest cost was indirect cost which was cost of lost productivity Rp 185.632,- ± 200.011/year. The lowest cost was cost of side effects. To conclude, the higher cost was cost of lost productivity. Costs in patients influenced by a number of medicine on prescription. Little medicine caused patients often went to primary health care centre. The higher frequency went to primary health care centre would be made a biggest cost.

Actions (login required)

View Item